Skip to content

Systematic IPP VS Symptomatic IPP in GERD Prevention After POEM for Achalasia. . A Comparative Retrospective Analysis

Interest of Systematic PPI Therapy After POEM vs Symptomatic Use of PPI Therapy in Prevention of Gastroesophageal Reflux Disease After POEM for Esophageal Achalasia. A Comparative Retrospective Analysis.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04740437
Acronym
IPPOEM-Retro
Enrollment
150
Registered
2021-02-05
Start date
2017-01-01
Completion date
2022-03-31
Last updated
2021-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achalasia, Gastroesophageal Reflux

Keywords

GERD, POEM, Achalasia, PPI, Esophagitis

Brief summary

POEM is a minimally invasive endoscopic therapy that is highly efficacy in the treatment of achalasia of any type. POEM has an increased risk of GERD. Systematic PPI therapy has never been studied for the prevention of post-POEM GERD. The investigators wish to retrospectively compare patients who have received routine PPI therapy vs. patients who don't.

Interventions

None listed

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \> 18 years old * Consent given * Achalasia all types with eckhardt score \> 3

Exclusion criteria

* Patient who is a minor or under judicial protection * Pregnant or breastfeeding woman * Contraindication to PPIs * Carrier of mediastinal and exogastric neoplasia * Patient on PPIs prior to the procedure for indication that does not allow for their discontinuation * Peptic esophagitis (Grade B, C or D) before or at the time of the procedure * Previous treatment with Heller myotomy

Design outcomes

Primary

MeasureTime frameDescription
Number of Esophagitis1 dayNumber of Esophagitis

Countries

France

Contacts

Primary ContactAntoine Debourdeau, MD
antoinedebourdeau@hotmail.com467330224
Backup ContactMathilde Charrier, MD
mathilde.snv@gmail.com467330224

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026